Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05597462 · ClinicalTrials.gov registry record · Phase 1
Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks
A Phase 1 study of Rosacea, sponsored by Journey Medical Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 2
- Study locations
NCT05597462 is a Phase 1 study of Rosacea that has completed, run by Journey Medical Corporation. The registered enrollment target is 60 participants, below the 240-participant average among 23 other Rosacea trials with a reported enrollment target (75% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05597462, a Phase 1 study of Rosacea, has completed, sponsored by Journey Medical Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this trial is to evaluate the effects of 16-week treatment with DFD-29 40 mg QD dose in comparison to Placebo on the skin, intestinal and vaginal microbiota.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Minocycline hydrochloride capsules
Study Locations (2)
New Mexico
- 3A Research, LLC - Las Cruces
Texas
- 3A Research, LLC - El Paso
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-09-30 |
| Est. Completion | 2023-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05597462
The ClinicalTrials.gov registry entry for NCT05597462 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 240-participant average among 23 other Rosacea trials with a reported enrollment target (75% lower). The listed sponsor is Journey Medical Corporation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05597462 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Mexico, Texas.
Frequently Asked Questions
What is clinical trial NCT05597462 about?
NCT05597462 is a clinical study titled "Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks". The purpose of this trial is to evaluate the effects of 16-week treatment with DFD-29 40 mg QD dose in comparison to Placebo on the skin, intestinal and vaginal microbiota.
What is the current status of trial NCT05597462?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2022-09-30. Estimated completion is 2023-05-30.
What conditions does trial NCT05597462 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT05597462?
The interventions under investigation include: Placebo (OTHER), Minocycline hydrochloride capsules (DRUG).
Who is sponsoring clinical trial NCT05597462?
This trial is sponsored by Journey Medical Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05597462 being conducted?
This trial has 2 study locations across New Mexico, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Topical Agent for Treatment of Red Skin
COMPLETED · Phase 1
-
Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea
COMPLETED · Phase 1
-
Timolol for the Treatment of Acne and Rosacea
COMPLETED · Phase 1
-
Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.
COMPLETED · Phase 1
-
A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea
COMPLETED · Phase 1
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.